Castle Biosciences, Inc. (CSTL) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

Castle Biosciences, Inc. (CSTL) closed at USD 33.80 on 2026-10-15, a change of +42.4 % over the past year, with a market capitalization of USD 976.36M.

Castle Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Castle Biosciences, Inc. key figures

Previous close

USD 33.80 (2026-10-15)

1-year change

+42.4 %

Market cap

USD 976.36M

Enterprise value

USD 746.21M

P/E ratio (trailing)

-49.94

P/E ratio (forward)

-34.99

EPS (trailing)

-0.64

EPS (forward)

-0.91

PEG ratio

n/a

Price to book

2.07

Revenue growth

20.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.82

Employees

1,002

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Castle Biosciences, Inc.

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Castle Biosciences, Inc. and compare it with other stocks.